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1.	SUMMARY		
	
Autoimmune	hepatitis	in	childhood	
Sadaf	Khan	
	
Autoimmune	hepatitis	(AIH)	is	an	inflammatory	process,	where	autoantibodies	
attack	and	damage	liver	cells.	Like	many	autoimmune	diseases,	aetiology	is	
unknown	and	it	affects	females	more	than	males.	It	is	characterised	by	both	the	
presence	of	autoantibodies	in	serum	and	by	high	activity	hepatic	infiltrate	patho-
histology.	There	are	two	types	of	pediatric	AIH	identified;	type	I	and	type	II.	The	
types	are	differentiated	on	serological	basis	mainly:	type	I	is	positive	for	smooth	
muscle	antibody	(SMA)	and/or	antinuclear	antibody	(ANA);	whereas,	type	II	is	
positive	for	antibody	to	liver	kidney	microsome	type	1	(ALKM1).	Moreover,	type	
II	clinical	presentation	is	more	acute,	usually	at	younger	age	as	well	as	lower	
levels	of	IgA.	In	comparison	to	type	I	pediatric	AIH,	often	present	at	older	
age/puberty.	Nevertheless,	the	response	to	treatment	and	prognosis	are	
comparable	in	both	types.	Genetic	predisposition	based	on	HLA	typing	has	been	
found	among	different	ethnicities.	The	treatment	for	both	types	is	long-	term	
immunosuppression	classically	with	steroids	and	azathioprine;	the	treatment	
aims	to	normalise	serology	and	liver	histology	–	remission.	Non-classic	
treatment	is	reserved	for	patients	that	are	resistant	to	classic	treatment;	i.e.	
immunosuppression	with	budesonide,	mycophenolate	mofetil	and	cyclosporine.	
Relapses	can	occur;	complete	remission	without	the	need	of	long-term	
immunosuppression	is	only	achieved	in	1	in	5	patients.	Pediatric	AIH	has	shown	
a	significant	association	with	other	autoimmune	diseases	like	autoimmune	
sclerosing	cholangitis,	inflammatory	bowel	disease,	autoimmune	thyroiditis,	
psoriasis	and	rheumatoid	arthritis;	some	share	clinical	features	and	are	
collectively	called	overlap	syndrome.		
	
Keywords:	Autoimmune	hepatitis,	immunosuppression,	pediatric		
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2.	SAŽETAK	
	
Autoimunosni	hepatitis	u	djece	
Sadaf	Khan	
	
Autoimuni	hepatitis	(AIH)	je	upalni	proces,	gdje	autoprotutijela	napadaju	i	
oštećuju	jetrene	stanice.	Poput	mnogih	autoimunih	bolesti,	etiologija	je	
nepoznata,	a	žene	su	više	zahvaćene	nego	muškarci.	Karakterizira	ga	prisutnost	
autoprotutijela	u	serumu	i	patohistologija	visoke	aktivnosti	hepatičkog	infiltrata.	
Postoje	dvije	vrste	dječjeg	AIH:	tip	I	i	tip	II.	Tipovi	se	uglavnom	razlikuju	
serološki:	tip	I	je	pozitivan	za	glatko	mišićna	antitijela	(SMA)	i/ili	antinuklearno	
antitijelo	(ANA);	dok	je	tip	II	pozitivan	za	protutijela	na	mikrosome	jetre	i	
bubrega	tipa	1	(ALKM1).	Štoviše,	klinička	prezentacija	tipa	II	je	akutnija,	obično	
u	mlađoj	dobi,	a	IgA	je	nižih	vrijednosti.	U	usporedbi	s	tipom	I	pedijatrijskog	AIH,	
često	prisutnog	u	starijoj	dobi/pubertetu.	Ipak,	odgovor	na	liječenje	i	prognoza	je	
usporediva	u	oba	tipa.	Genetska	predispozicija	na	temelju	HLA	tipizacije	
pronađena	je	među	različitim	nacionalnostima.	Liječenje	oba	tipa	je	dugotrajna	
imunosupresija,	tipično	-	steroidima	i	azatioprinom;	liječenje	nastoji	
normalizirati	serološki	nalaz	i	histologiju	jetre,	odnosno	postići	remisiju.	
Netipičan	tretman	je	rezerviran	za	bolesnike	koji	su	otporni	na	tipičan	tretman;	
tj.	imunosupresija	s	budesonidom,	mikofenolat	mofetilom	i	ciklosporinom.	Može	
doći	do	recidiva;	potpuna	remisija	bez	potrebe	za	dugotrajnom	imunosupresijom	
postiže	se	samo	u	jednoj	od	5	bolesnika.	Dječji	AIH	je	pokazao	značajnu	
povezanost	s	drugim	autoimunim	bolestima	kao	što	su	autoimuni	sklerotični	
kolangitis,	upalna	bolest	crijeva,	autoimuni	tireoiditis,	psorijaza	i	reumatoidni	
artritis;	neki	dijele	kliničke	osobine	i	zajednički	se	nazivaju	sindrom	preklapanja.	
	
Ključne	riječi:	Autoimuni	hepatitis,	imunosupresija,	pedijatrija	
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3.	INTRODUCTION	
	
Autoimmune	hepatitis	(AIH)	is	inflammatory	disease	of	liver	of	unknown	
aetiology.	Like	many	other	autoimmune	disease	it	affects	mainly	females.	In	
pediatrics	and	young	adults	autoimmune	hepatitis	usually	presents	in	acute	form	
and	often	has	a	more	aggressive	course	than	a	middle	aged	and	elderly	patients	
[1].	It	can	be	divided	into	two	types	Type	I	and	Type	II,	the	classification	is	based	
on	the	presence	of	certain	autoimmune	antibodies,	age	at	onset,	severity	and	
presence	of	certain	immunoglobulins	[1].		Table	1	enlists	some	of	the	main	
differences	between	type	I	and	type	II:	
	
	 Type	I	 Type	II	
Autoimmune	antibodies	 ANA	+,	SMA	+	 LKM1	+,	LC1	+	
Age	of	onset	 Puberty		 Younger	even	infancy	
Severity		 Less	serious	 More	serious	
Immunoglobulins	 é	IgG,	15%	normal		 é	IgG,	25%	normal,		
IgA	deficiency	common	
Liver	enzymes	 é	ASL/ALT	 é	ASL/ALT	and	bilirubin	
Table	1:	Type	I	v/s	Type	II	autoimmune	hepatitis	in	children.	Derived	from	
information	obtained	from	Miele	–	Vergani	et	al	2009	[2,3]	
	
	
Figure	1:	(A)	Normal	(B)	Autoimmune	hepatitis	[34]	
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Autoimmune	hepatitis	is	a	progressive	liver	disease.	Apart	from	serology	and	
autoimmune	antibodies,	it	is	also	characterised	by	liver	histology	(as	shown	in	
figure	1)	by	interface	hepatitis	especially	in	cases	of	unknown	aetiology	[1].	
Autoimmune	hepatitis	responds	to	immunosuppressive	treatment.	Furthermore,	
autoimmune	liver	inflammation	in	children	is	due	to	these	two	liver	disorders:	a)	
classical	AIH	and	b)	AIH/sclerosing	children	cholangitis	overlap	syndrome	
(ASC)[2,3].	ASC	has	characteristic	interface	hepatitis	along	with	bile	duct	
damage.	
	
4.	ROLE	OF	GENETICS	
	
Through	our	knowledge	of	other	autoimmune	disease,	AIH	is	also	believed	to	
have	link	to	genetics,	predisposing	some	children	to	AIH	as	compared	to	others.	
Genetic	study	plays	a	crucial	role	in	establishing	such	patterns.	HLA	typing	
reveals	that	population	originating	from	northern	Europe,	and	have	type	1	AIH	
are	also	associated	with	the	possession	of	the	human	leukocyte	antigen	(HLA)	
DRB1*03.	Type	1	AIH	is	similar	to	AIH	in	adults	[2,5].	Whereas,	the	adult	patients	
who	are	HLA	of	DRB1*04	do	not	predispose	to	pediatric	AIH,	and	can	even	wield	
a	protective	role	against	AIH	of	childhood.	
HLA-	DRB1*07	is	associated	with	Type	2	AIH	[6].	HLA	typing	differs	across	
regions	and	ethnicities.	For	instance,	in	South	America,	possession	of	the	HLA	
DRB1*1301	allele,	predisposes	to	pediatric	AIH	type	1,	as	well	as	is	associated	
with	frequent	infection	with	the	endemic	hepatitis	A	virus	[6].	
AASLD	(American	Association	for	the	Study	of	Liver	Diseases)	shows	that	
Pediatric	AIH	patients	with	either	antiLKM1-	or	ANA/SMA-positive,	have	
isolated	partial	deficiency	of	the	HLA	class	III	complement	component	C4,	which	
is	genetically	determined.	
Additionally,	Type	2	AIH	can	present	as	a	part	of	the	autoimmune	
polyendocrinopathy-candidiasis-ectodermal	dystrophy	(APECED)	syndrome;	its	
an	autosomal-recessive	monogenic	disorder,	can	comprise	of	liver	disease	is	
about	20%	of	cases.	[7,8]	
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5.	CLINCAL	PRESENTATION	
	
Clinically	AIH	can	presents	as	three	patterns	of	the	disease	presentation:	[2]	
1. Viral	presentation:	about	40%	of	AIH	patients,	the	clinical	picture	is	
indistinguishable	from	that	of	an	acute	viral	hepatitis;	featuring	
nonspecific	symptoms	of	malaise,	nausea,	vomiting,	anorexia,	and	
abdominal	pain,	followed	by	jaundice	with	dark	urine,	and	pale	stools.	
Some	children,	especially	those	who	are	anti-LKM1	positive	(type	2),	
often	develop	acute	hepatic	failure	with	grade	2-4	hepatic	
encephalopathy	in	two	to	eight	weeks	from	onset	of	symptoms.		
2. Insidious	presentation:	about	one	third	of	patients	have	insidious	onset,	
with	presentation	characterized	by	progressive	fatigue,	frequent	jaundice,	
headache,	anorexia,	amenorrhea,	and	weight	loss,	the	disease	may	not	be	
diagnosed	for	several	months	and	even	years	due	to	vague	clinical	
picture.		
3. Portal	hypertension	presentation:	one	tenth	of	the	patients	show	no	
history	of	jaundice,	such	cases	are	diagnosed	later	when	they	present	
with	complications	of	portal	hypertension,	such	as	splenomegaly,	
hematemesis	from	esophageal	varices,	bleeding	diathesis,	chronic	
diarrhea,	and	weight	loss.	[2]	
Since	there	is	quite	some	variability	in	pediatric	AIH,	the	disease	should	be	
suspected	and	ruled	out	in	all	children	presenting	with	symptoms	and	signs	of	
liver	pathology.	The	course	of	the	disease	may	differ,	with	flares	and	
spontaneous	remissions,	a	pattern	that	can	mislead	and	cause	delayed	diagnosis	
and	treatment.	Physical	exam	of	most	of	these	children	will	have	clinical	signs	of	
an	underlying	chronic	liver	disease,	like	cutaneous	stigmata	(spider	nevi,	
leukonychia,	palmar	erythema,	striae),	firm	liver,	and	splenomegaly.	The	
ultrasound	of	these	patients	often	features	nodular	and	heterogeneous	liver	
parenchyma.	[3]	
In	this	thesis,	serological	data	and	patho-histological	records	of	pediatric	
patients	are	reviewed	that	were	referred	to	Rebro	hospital	Zagreb,	Croatia;	i.e.	
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immunology	and	histology	essentially.	In	the	last	34	years	forty	cases	of	pediatric	
AIH	have	been	recorded	in	the	pediatric	department	of	University	Hospital	
Centre	Zagreb,	Croatia.	In	this	paper	these	forty	cases	are	used	to	study	the	
characteristic	features	and	reoccurring	pattern	among	these	patients	based	on	
the	following	factors:	
• Age	at	the	onset	of	the	disease	
• Gender	
• AIH	Type	I/II	
• Autoimmune	antibodies	(ANA,	ASMA,	AGLM,	LKM,	ALA)	
o At	the	onset	
o During	the	course	of	the	disease	
• ESR	
• Immunoglobulin	A	
• Immunoglobulin	G	
• Ratio	A/G	(albumin:	calculated	globulin)	
• Liver	biopsy	(interface	hepatitis/severity)	
• Presence	of	another	known	autoimmune	disease		
• Presence/absence	of	inflammatory	bowel	disease	(IBD)	
• Treatment	
o Classical	à	steroids	for	induction	and	azathioprine	for	the	rest	
o Non-classical	
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	 TYPE	I	 TYPE	II	
Mean	age	at	onset	 11.2	years	 4.0	years	
Females	%	 55%	 0%	
Mode	of	presentation	(%)		
Acute	hepatitis		
	
	
26%	
	
	
0%	
	
Acute	liver	failure		 4%	 0%	
Insidious	onset		 17%	 100%	
Complication	of	chronic	liver	
disease	
35%	 0%	
Associated	immune	diseases	
(%)		
45%	 0%	
Sclerosing	cholangitis	(%)	 26%	 0%	
Inflammatory	bowel	disease	
(%)	
25%	 0%	
ANA/SMA	(AGLM)	(%)	 50%	 	
Anti-LKM1	(%)	 0%	 100%	
	Anti-SLA	(%)	 7.5%	 	
Increased	IgG	level	(%)	 61,5%	 0%	
Decreased	Ratio	A/G	 10%	 0%	
Increased	ESR	 55%	 Normal	(0%)	
Interface	hepatitis	(%)	 66%	 100%	
Biliary	features	(%)	 28%	 0%	
Table	2:	Clinical,	Immunological,	and	Histological	Features	at	Presentation	of	AIH	
referred	to	University	Hospital	Centre	Zagreb	patients	[4].	Modified	from	Vergani	
et	al	2009	[1]		
	
Type1	AIH	affects	both	children	and	adults	and	has	characteristic	autoimmune	
antibody	against	smooth	muscle	cells	(SMA)	plus/minus	antinuclear	antibodies	
(ANAs).	Whereas,	type	2	AIH	is	primarily	a	pediatrics	disease;	and	is	
characterized	by	the	presence	of	antibodies	to	liver-kidney	microsome	type	1	
(anti-LKM1)	plus/minus	anti-liver	cytosol	type	1	(anti-LC1).	[2,3]	Both	type	1	
and	type	2	AIH	responds	well	to	immunosuppressive	treatment.	If	left	untreated,	
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it	generally	progresses	rapidly	to	cirrhosis	and	liver	failure.	Like	most	
autoimmune	diseases	AIH	has	higher	incidence	of	females	as	compare	to	males.	
The	epidemiology	of	childhood	AIH	is	unknown,	but	2/3	of	the	AIH	cases	in	
children	is	type	1	AIH	and	usually	presents	around	puberty,	while	type	2	AIH	
tends	to	present	at	a	younger	age	some	even	during	infancy.	Laboratory	work	
usually	shows	increased	IgG	at	presentation	in	both	types,	although	about	15%	
of	children	with	AIH	type	1	and	25%	AIH	type	2	may	have	normal	levels	[2].	
Whereas,	IgA	deficiency	is	often	seen	in	AIH	type	2	[2].	Studies	show	that	
severity	of	disease	is	more	or	less	similar	in	both	types,	but	type2	AIH	patients	
have	higher	levels	of	bilirubin	and	transaminases	at	presentation	than	those	who	
are	type	1	and	present	significantly	more	frequently	with	fulminant	hepatic	
failure	as	reflected	by	bilirubin	and	transaminases	values	[2].		
As	far	as	patho-histology	is	concerned	the	severity	of	interface	hepatitis	at	the	
time	of	diagnosis	is	similar	in	both	type	1	and	type	2,	but	cirrhosis	on	initial	
biopsy	is	more	common	to	find	in	type	1	in	comparison	to	type	2	AIH,	indicating	
a	more	chronic	course	of	disease	in	type	1.	Furthermore,	progression	to	cirrhosis	
while	on	treatment	is	more	frequent	in	type	1	AIH.	In	both	types	of	AIH,	presence	
of	antibodies	to	soluble	liver	antigen	(SLA)	suggests	a	more	severe	form	along	
with	increased	tendency	to	relapse,	about	one	in	two	patients	of	AIH	are	SLA	
positive,	equal	between	the	both	types	of	AIH.	[4]	One	fifth	of	al	AIH	of	patients	
has	other	autoimmune	disorders—like	thyroiditis,	vitiligo,	type	1	diabetes,	
inflammatory	bowel	disease	(IBD),	and	nephrotic	syndrome	and	approximately	
40%	have	a	positive	family	history	of	autoimmune	disease.	[2]	
	
6.	DIAGNOSIS	
	
Diagnosis	of	pediatric	AIH	is	mainly	based	on	serology,	rheumatology	and	liver	
histology;	i.e.	a	series	of	positive	and	negative	criteria.	[9,10]	Liver	biopsy	is	a	
requirement	to	establish	the	AIH	diagnosis.		
The	second	criterion	of	AIH	diagnosis	is	elevated	IgG	levels	and	serum	
transaminases	along	with	the	presence	of	autoimmune	antibodies	ANA,	SMA,	or	
anti-LKM1.	The	International	Autoimmune	Hepatitis	Group	(IAIHG)	introduced	a	
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‘negative	criteria	for	the	diagnosis	of	AIH	that	included	hepatitis	B	or	C	viral	
infection	or	Wilson’s	disease	and	alcohol,	among	the	positive	criteria	mentioned	
earlier	[9,10].	The	IAIHG	positive	and	negative	criteria	have	proven	to	be	a	useful	
scoring	system	for	the	diagnosis	of	AIH	as	well	as	for	research	purposes.	It	is	a	
simple	scoring	system	based	on	autoimmune	antibodies,	IgG,	histology,	and	
omission	of	viral	hepatitis	[11].	One	of	the	cons	of	the	IAIHG	scoring	system	is	
that	it	has	been	produced	for	adult	AIH	and	may	not	necessarily	take	into	
account	the	peculiarities	of	pediatric	AIH.	
	
6.1.	Autoantibodies		
As	mentioned	earlier	autoantibodies	detection	is	an	important	criterion	for	
diagnosis	and	differentiating	between	types	of	AIH.		These	are	detected	using	a	
technique	called	indirect	immunofluorescence	on	a	freshly	prepared	rodent	
substrate	kidney,	liver,	and	stomach	tissue	[48],	to	detect	anti	nuclei	
autoantibodies	(ANA),	smooth	muscle	autoantibodies	(SMA),	and	anti-liver-
kidney	microsome	type	1	(antiLKM1)	autoantibodies.	It	must	be	noted	that	
autoantibodies	positivity	is	not	diagnostic	of	AIH,	as	other	liver	diseases	and	
viral	hepatitis,	Wilson’s	disease	and	non-alcoholic	steatohepatitis	[49]	can	also	
present	with	low	titre	autoantibodies.	Hence,	the	titre	value	significant	for	AIH	is	
also	important.	The	immunofluorescence	technique	is	clinician	dependent	and	
can	be	a	cause	of	discrepancies	in	results	along	with	the	possibility	of	false	
positive	results	e.g.	antiLKM1	can	often	be	confused	with	AMA	due	to	similar	
pattern.	International	Autoimmune	Hepatitis	Group	(IAIHG)	has	issued	
guidelines	in	order	to	standardise	the	laboratory	data,	along	with	titre	values	to	
differentiate	between	adults	and	pediatric	population	[48].	,	In	healthy	children	
autoantibody	reactivity	is	uncommon,	so	that	titres	of	1/20	for	ANA	and	SMA	
and	1/10	for	anti-LKM1	are	clinically	significant.	In	comparison	to	adults	
autoantibody	reactivity	at	1/10	is	common,	1/40	in	adults	is	considered	
clinically	relevant.	
	
Other	important	autoantibodies	are,	anti-neutrophil	cytoplasm	antibody	(ANCA),	
and	soluble	liver	antigen	(SLA)	antibody;	ANCA	can	be	positive	in	autoimmune	
hepatitis.	The	autoantibody	peripheral	antinuclear	neutrophil	antibody	(pANNA)	
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is	found	in	AIH	as	well	as	other	autoimmune	diseases	like	inflammatory	bowel	
disease	(IBD)	and	sclerosing	cholangitis;	it	is	never	indicative	of	type	II	AIH	[50].	
On	the	other	hand	anti-SLA	autoantibody	is	also	found	in	50%	of	cases	of	both	
types	AIH;	the	presence	of	anti-SLA	autoantibody	is	indicative	of	a	more	severe	
form	of	AIH	[50].	
There	are	always	some	cases	of	AIH	where	the	autoantibodies	are	undetectable.	
These	sero-negative	children	are	still	treated	with	immunosuppression	like	
seropositive	types.	[10,	51]	
	
6.2.	Histology	
The	typical	histological	picture	of	AIH	liver	includes:		
• Inflammatory	infiltrate:	Presence	of	dense	mononuclear	and	
plasma	cell	infiltration	of	the	portal	areas,	expanding	into	the	liver	
lobule	(Fig.	1A)	
• Interface	hepatitis:	Peri-lobule	destruction	of	the	hepatocytes	
along	with	erosion	of	the	limiting	plate		
• Bridging	collapse:	Connective	tissue	collapse	due	to	hepatocyte	
death	and	spreading	from	the	portal	area	into	the	lobule		
• And	hepatic	regeneration	with	‘‘rosette’’	formation		
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Figure	2	shows	the	typical	features	of	hepatic	patho-histology	of	AIH;	it	
comprises	mononuclear	inflammation,	high	activity	infiltrate,	piecemeal	
necrosis,	bridging	necrosis,	and	fibrosis	of	varied	severity	depending	on	the	
stage	of	liver	damage.	The	slides	were	obtained	from	the	pathology	department	
at	University	Hospital	Centre	Zagreb,	Croatia.	
	
6.3.	HLA	typing		
See	section	4,	Role	of	genetics.	
	
7.	PATHOGENESIS	
	
AIH	is	of	unknown	aetiology,	it	is	believed	that	both	genetic	and	environmental	
play	part.	Histologically,	AIH	is	characterised	by	dense	portal	mononuclear	cell	
infiltrate	surrounding	the	parenchyma;	the	infiltrate	consists	of	T	and	B-
lymphocytes,	macrophages,	and	plasma	cells	[58,59].	For	the	reason	unknown,	
this	strong	inflammatory	cellular	reaction	is	initiated	leading	to	liver	damage.	An	
auto-antigenic	liver	peptide	is	recognised	by	CD4	T	lymphocytes.	An	HLA	class	II	
presents	the	auto-antigenic	liver	peptide	to	naïve	CD4	T-helper	cells	(Th0)	and	
it’s	then	activated.	The	activated	Th0	then	differentiate	into	various	cytokines	
triggering	a	cascade	of	immune	reactions.		Macrophages	produce	interleukin	12	
(IL),	IL-2	and	interferon	(IFN)-gamma;	this	increases	HLA	class	I	sensitivity	and	
thus	elevates	CD8	T	cell	cytotoxic	activity	on	hepatocytes	as	well	as	induction	of	
HLA	class	II	on	liver	cells.	Elevated	levels	of	IL-4	triggers	differentiation	of	T-
helper	type	2	(Th2)	cells	from	Th0	which	mainly	secretes	IL-4,	IL-10,	and	IL-13,	
this	leads	to	autoantibody	production	by	B	lymphocytes.	Furthermore,	recent	
research	shows	that	in	the	presence	of	transforming	growth	factor	beta	(TGF-b)	
and	IL-6,	a	population	of	Th17	cells	arise;	Th17	cells	have	shown	to	play	an	
important	role	in	autoimmunity	as	well	as	inflammation.	Regulatory	T	cells	CD4	
CD25	(T-regulatory	cells),	also	a	derivative	of	TGF-b	is	responsible	for	the	
recognising	the	auto-antigen.	When	there	is	a	flaw	in	this	regulatory	system,	
autoimmunity	persists.	[59-62]	
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This	regulatory	mechanism	has	been	an	area	of	interest	over	that	last	three	
decades,	in	order	to	understand	autoimmune	pathogenic	pathways	and	immune-
regulations.		Defective	T	regulatory	cells	have	been	seen	in	AIH.	Recent	studies	
have	demonstrated	that	in	AIH	type	2	the	main	perpetrator	is	T-cells	[59,	63].	
There	has	been	evidence	that	suggests	that	elevated	levels	of	CD4	T	cells	and	
CD8	T	cells	producing	IFN-gamma	is	linked	with	molecular	hepatic	damage.	[63]	
In	conclusion	various	studies	and	evidence	indicates	a	multifactorial	cellular	
immune	attack.		
	
8.	TREATMENTS	AND	MANAGEMENT	
	
The	main	aim	of	treatment	is	clinical	remission,	complete	serological	and	
histological	resolution	of	inflammation	and	liver	damage.	The	long-term	goal	is	
to	sustain	remission	without	the	need	for	pharmacotherapy.	AIH	remission	is	
defined	as	“the	resolution	of	symptoms;	normalization	of	levels	of	serum	
aminotransferase,	serum	bilirubin,	and	g-globulin/IgG;	and	an	improvement	of	
liver	histology	either	to	normal	or	to	only	mild	portal	hepatitis”[64].	Serological	
normalisation	alone	is	not	sufficient	to	deduce	normal	hepatic	normalisation.	
The	goals	of	the	AIH	can	be	stated	as	follows:	[65]	
• Initial	aim	is	normalization	of	liver	aminotransferase		
• Normalization	of	the	g-globulin	and	immunoglobulin	G	levels		
• Histological	normalization,	reducing	hepatic	infiltrate	
• Quaternary	end	point:	resolution	of	fibrosis		
• Final	goal	is	to	achieve	sustained	remission	without	the	need	for	drug	
therapy	and	essentially	preserving	the	hepatic	function	
	
8.1.	Classic	v/s	non-classic	
Classically	AIH	treated	with	steroids	initially	to	induce	remission;	prednisone	
20-30mg/day	often	combined	with	azathioprine.	Azathioprine	may	cause	dose-
dependent	hepatotoxicity	in	some	rare	severe	AIH	cases	[1].	To	avoid	the	side	
effects	of	azathioprine	on	decompensated	liver,	it	can	be	commenced	few	weeks	
after	the	steroids	[35].	Azathioprine	in	combination	with	prednisolone	is	
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preferred	as	the	side	effects	are	fewer	as	compared	to	prednisolone	alone	i.e.	
10%	v/s	44%.	[35]	Furthermore	protection	to	bone	against	long-term	use	of	
steroids	is	also	suggested.	Alternate	steroids	therapy	is	
Non-classical	treatment	options	for	AIH	is	considered	to	minimise	adverse	
effects	of	the	classical	treatment	or	when	there	is	tolerance	observed	with	
classical	treatment.	Remission	and	relapse	is	determined	based	on	liver	function	
test	(AST	and	ALT)	levels.	One	of	the	alternative	therapy	is	Budesonide	in	
addition	with	azathioprine	can	be	considered	for	patients	with	comorbidities	
that	can	worsen	with	prednisone	administration.		
	
Budesonide	has	a	higher	affinity	for	the	glucocorticoid	receptor	as	compared	to	
prednisolone	but	about	90%	of	it	is	cleared	through	hepatic	first	pass	
metabolism.	Study	shows	that	remission	is	achieved	with	budesonide	in	58-83%	
of	cases	along	with	improved	tolerability	[36,	37].	Another	double	blind	
randomised	study	consisted	of	203	AIH	patients	that	were	given	either	
budesonide	plus	azathioprine	or	prednisone	plus	azathioprine;	the	results	
showed	remission	at	six	months	with	budesonide	in	60%	whereas	40%	with	
prednisone	[38].		
Although	promising	results	were	achieved	with	budesonide	the	1st	pass	hepatic	
metabolism	is	a	risk	factor	for	corticosteroid	induced	side	effects.	This	limits	the	
use	of	budesonide	in	patients	with	severely	damaged	liver	[39].	
	
Mycophenolate	mofetil	(MMF)	is	a	strong	immunosuppressive	drug,	with	side	
effects	including	diarrhoea	and	bone	marrow	suppression	[40].	However	a	study	
has	shown	a	decreased	hepatic	activity	index	along	with	normal	transaminases	
achieved	with	three	to	nine	months	use	of	MMF;	the	patients	used	in	the	study	
were	either	intolerant	or	not	effected	by	azathioprine	[41].	Promising	results	of	
MMF	were	recorded	in	a	pediatric	study	too	[42].	The	use	of	MMF	is	restricted	to	
azathioprine	tolerance/resistance.	It	is	a	teratogen	thus	it	is	not	used	in	women	
planning	to	get	pregnant.	[35]	
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Calcineurin	Inhibitors	aka	cyclosporine	A	(CyA)	has	shown	positive	results	in	
inducing	and	maintaining	remission,	especially	in	pediatric	population	with	AIH	
[43,44].	Another	agent	called	tacrolimus	is	more	potent	than	CyA	and	a	studies	
has	shown	minimal	side	effects	[45]	with	improved	transaminases,	IgG	along	
with	reduced	inflammatory	index	[46].	A	study	done	in	Virginia	on	AIH	patients	
treated	with	tacrolimus	has	observed	increased	remission	rates.	[47].	
Tacrolimus	seems	to	be	much	better	choice	of	drug	especially	for	AIH	patients	
tolerant	to	classical	therapy,	but	long-term	data	and	follow	up	studies	are	
required	to	be	certain.	
	
8.2.	When	to	start	
If	left	untreated	autoimmune	hepatitis	has	poor	prognosis,	while	patients	with	
adequate	immunosuppressive	therapy	have	good	prognosis	[12,13].	
Autoimmune	hepatitis	is	highly	responsive	to	immunosuppression,	and	
treatment	should	be	started	straightaway	to	avoid	progression	of	liver	fibrosis	
and	failure.	The	treatment	is	targeted	to	decrease	liver	inflammation	in	order	to	
reach	remission,	improve	symptoms,	prevent	liver	fibrosis,	prolong	survival	and	
delay	the	need	of	liver	transplant	[20].	The	response	to	therapy	is	dependent	on	
disease	severity	at	the	time	of	presentation.	Even	though	cirrhosis	is	present	in	
44	to	80%	of	children	at	diagnosis	[21,22,23]	mortality	rate	can	be	delayed	and	
clinical	stability	is	usually	achieved,	with	well-regulated	long-term	therapy	along	
with	a	good	quality	of	life	in	pediatric	AIH.	
8.3.	Duration	
As	each	cases	comes	with	individual	characteristics	and	response	to	therapy,	the	
optimal	duration	of	immunosuppressive	treatment	for	pediatric	AIH	is	still	a	
matter	of	research.	Treatment	withdrawal	is	dependent	on	liver	histology,	it	is	
only	recommended	to	stop	the	therapy	if	patho-histology	shows	little	to	no	
inflammation.		This	usually	takes	one	to	two	years	of	normal	liver	function	tests,	
normal	immunoglobulin	gamma	levels	and	minimal	to	zero	autoantibodies	titres.		
The	relapses	are	more	common	just	before	puberty	and	within	the	first	three	
years	of	diagnosis.	Hence	is	recommended	to	avoid	therapy	withdrawal,	just	
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before	puberty	and	first	three	years	of	treatment.	Treatment	withdrawal	can	
successfully	be	achieved	in	about	one	fifth	of	the	patients	with	type	1	AIH	but	
seldom	in	type	2	AIH	[2].	Most	of	the	patients	require	a	long-term	treatment	and	
families	may	require	counselling	[11].	The	AIH	disease	activity	correlates	with	
IgG	levels,	presence	and	titres	of	autoimmune	antibodies	and	is	important	to	
monitor	these	values	to	maintain	disease	control	and	avoid	flares	[33].	
	
9.	PROGNOSIS	
	
Overall	prognosis	of	AIH	in	pediatric	population	is	good	with	
immunosuppressive	therapy,	even	among	patients	that	presented	with	cirrhosis.	
Survival	rate	is	high	with	a	very	good	quality	of	life	on	low	dose	
immunosuppression	therapy.	8.5%	of	patients	from	King’s	College	Hospital	
Pediatric	Liver	Centre	required	transplant	due	to	development	of	end-stage	liver	
disease;	the	transplant	was	required	8-14	years	post	diagnosis	[2].	The	patients	
that	present	with	acute	liver	failure	are	usually	more	resistant	to	treatment	and	
initial	therapeutic	effect	is	more	difficult	to	achieve.	[27]	
	
Table	3	Response	to	Treatment	and	Outcome	in	Children	with	Autoimmune	
Hepatitis	type	I	and	type	II	[2,25]	
	 TYPE	I	 TYPE	II	
Remission	rate	(%)	 97	 98	
Median	time	to	remission	 6	 9	
Relapse	rate	(%)	 42	 46	
Cessation	of	treatment	
(%)	
19	 0	
Liver	transplant	rate	(%)	 6	 13	
Disease	recurrence	post-
transplant	(%)	
0	 0	
Table	3:Data	are	from	patients	treated	at	the	King’s	College	Hospital	Tertiary	
Pediatric	Liver	Centre	[2,25]	
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resulting	in	relapse	[26].	In	severe	cases,	the	risk	of	relapse	is	greater	if	steroids	
schedule	is	an	alternate-day	therapy,	the	aim	of	alternate-day	steroid	schedule	is	
to	minimise	its	side	effect	on	child’s	growth.	However,	it	has	seen	that	small	daily	
doses,	have	better	effect	in	maintaining	disease	control.	It	minimises	the	need	for	
high-dose	steroid	dosage	during	relapses	and	thus	fewer/less	severe	side	effects	
i.e.	abating	negative	affect	on	final	height	[25,27].	Classical	treatment	of	AIH	
consists	of	prednisolone	(also	known	as	prednisone)	2	mg/kg/d	maximum	60	
mg/	d,	this	is	gradually	decreased	over	a	period	of	4	to	8	weeks,	according	to	
corresponding	decline	of	serum	transaminase	levels,	bringing	it	to	a	
maintenance	dose	of	2.5	to	5	mg/d	[28,30].		
	
Usually	an	80%	decrease	of	the	serum	aminotransferase	levels	is	achieved	in	the	
first	eight	weeks,	but	lowering	it	to	normal	range	may	take	months	[28,31].	
Weekly	liver	function	test	must	be	carried	out	in	first	6-8	weeks	of	therapy	to	
adjust	steroid	dosage	and	thus	minimising	steroid	side	effects	in	children.	
Azathioprine	may	be	added	in	the	presence	of	severe	steroid	side	effects,	or	as	an	
adjuvant	drug	if	the	serum	transaminase	levels	fail	to	decrease	with	steroid	
treatment	alone.	The	starting	dose	is	0.5	mg/kg/d,	which	in	the	absence	of	signs	
of	toxicity	is	increased	up	to	a	maximum	of	2.0	to	2.5	mg/kg/d	until	the	desired	
serum	transaminases	values	are	achieved.	In	some	cases	a	combination	of	
steroids	and	azathioprine	is	prescribed	from	the	start,	but	caution	is	
recommended	because	azathioprine	can	cause	hepatotoxicity,	especially	in	
patients	with	severe	jaundice.	A	preliminary	report	suggests	that	measurement	
of	the	azathioprine	metabolites	6-thioguanine	and	6-methylmercaptopurine	is	
useful	in	identifying	drug	toxicity	and	compliance	issues.	Additionally,	the	
metabolite	6-thioguanine	is	considered	therapeutic	for	inflammatory	bowel	
disease	[32].	
	
11.	TRANSPLANT	
	
Liver	transplant	is	indicate	in	end-stage	AIH/liver	disease	as	the	last	resource	
when	the	conventional	treatment	methods	are	not	effective	often	due	to	long	
term	hepatic	damage	prior	the	start	of	the	immune	suppression	therapy.	These	
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patients	usually	present	with	fulminant	liver	failure	along	with	encephalopathy	
[1].	Two	patients	of	Rebro	KBC	Zagreb	hospital	patients	were	indicated	for	liver	
transplant,	which	makes	it	5%	of	the	data	collected.	Whereas	another	AIH	
pediatric	study	done	at	Kings	Hospital	London	by	Mieli-Vergani	recorded	that	
10-20%	children	diagnosed	with	AIH	require	liver	transplant,	with	20%	
recurrence	rate	with	transplanted	liver	[1].	Insufficient	data	is	available	to	
calculate	recurrence	rate	with	liver	transplant	patients	from	Rebro	KBC	Zagreb	
hospital	patients.	As	the	recurrence	is	possible	even	after	liver	hence	the	state	of	
immunosuppression	must	be	maintained	using	steroids,	higher	than	non-
transplant	AIH	patient.	Immunosuppression	is	also	recommended	to	avoid	graft	
versus	host	disease.	[27]	
				
12.	DISCUSSION	
The	limitations	and	AIH	associations	with	other	autoimmune	diseases	are	as	
follows:	
	
12.1.	Limitations	
There	are	some	limitations	that	must	be	considered	when	reviewing	the	
research	data	as	some	patients	with	primary	biliary	cirrhosis	(PBC)	may	present	
features	of	autoimmune	hepatitis	[14,15]	another	differential	diagnosis	is	
primary	sclerosing	cholangitis	(PSC)	[16].	As	found	in	the	pediatric	patients	
database	from	Rebro	hospital	Zagreb	these	cases,	termed	as	overlap	syndromes,	
are	subject	to	debate	and	further	research	and	classification	[17].	The	treatment	
via	immunosuppressive	therapy	in	AIH	patients	also	has	divided	opinions,	but	
majority	of	experts	agree	with	the	need	to	use	immunosuppression	given	the	
high	activity	inflammatory	hepatitis	infiltrate	[18].	The	distinction	between	
overlap	syndrome	and	primary	AIH	and	PBC	or	PSC	associated	AIH	is	done	by	
the	positive	and	negative	criteria	[19]	of	diagnosis	[see	diagnosis	section].		
Secondly,	most	research	and	data	available	about	AIH	is	based	on	adult	AIH	and	
thus	some	discrepancies	may	exist	in	areas	like	clinical	features,	aetiology,	
response	to	treatment	and	prognosis.	Reason	being	pediatric	AIH	is	not	as	
common	as	in	adult	population.	
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12.2.	In	relation	to	other	autoimmune	diseases	
AIH	in	pediatric	population	is	sometimes	associated	with	other	autoimmune	
disease;	the	correlation	and	pattern	of	such	associations	vary	from	case	to	case.	
Some	of	the	common	association	of	AIH	is	with	autoimmune	sclerosing	
cholangitis	(ASC),	primary	biliary	cirrhosis	(PBC),	primary	sclerosing	cholangitis	
(PSC),	inflammatory	bowel	diseases	(IBD);	ulcerative	colitis/crohn’s	disease	and	
rheumatoid	arthritis	(RA).		
ASC	presents	with	typical	presentation	of	autoimmune	disease	i.e.	elevated	IgG	
increased	titres	of	autoantibodies	especially	ANA,	SMA	along	with	interface	
hepatitis	[53].	About	5-10%	of	PSC	and	PBC	patients	have	serology-indicating	
AIH	and	vice	versa	and	some	patients	shares	clinical	pictures	too.		A	Mayo	Clinic	
study	comprised	of	225	AIH	patients	showed	a	significant	association	between	
AIH	and	other	autoimmune	diseases	[54].		This	study	showed	that	18%	of	the	
patients	with	overlapping	features;	i.e.	7%	with	AIH-PBC,	6%	with	AIH-PSC,	and	
11%	with	AIH-autoimmune	cholangitis	(AIC).	[55,	56,	57]	
	 	
13.	CONCLUSION	
	
Since	the	follow	up	data	from	the	University	Hospital	Centre	Zagreb	patients	is	
out	of	this	thesis	scope.	The	detailed	information	about	their	duration	of	
treatment,	remission	and	relapse	is	not	reviewed.	In	order	to	obtain	a	whole	
picture	of	treatment	outcome	of	AIH,	a	more	detailed	and	long-term	review	is	
needed.	Nevertheless,	it	is	safe	to	conclude	that	a	long-term	management	is	
required	for	pediatric	AIH,	which	requires	regular	serological	and	patho-
histological	(if	serology	indicates	hepatic	pathology)	monitoring	to	ensure	
remission	and/or	detect	relapse	so	that	appropriate	therapy/intervention	can	be	
adjusted	accordingly.		
New	drugs	have	been	studied	for	the	achievement	and	maintenance	of	remission	
with	minimal	or	no	side	effects.	Hopefully,	future	studies	will	allow	us	to	pin	
point	the	trigger	of	pathogenesis	of	AIH	so	that	a	more	targeted	therapy	can	be	
devised.	
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